Ann Surg Treat Res.  2022 Feb;102(2):73-82. 10.4174/astr.2022.102.2.73.

Subsequent pregnancy and long-term safety after breast cancer: a retrospective analysis of Korean health insurance data

Affiliations
  • 1Artificial Intelligence and Big-Data Convergence Center, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
  • 2Department of General Surgery, Breast Cancer Center, Gachon University Gil Medical Center, Incheon, Korea
  • 3Department of Medical Oncology, Gachon University Gil Medical Center, Incheon, Korea
  • 4Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea

Abstract

Purpose
Long-term safety of pregnancy after breast cancer (BC) remains controversial, especially with respect to BC biological subtypes.
Methods
We analyzed a population-based retrospective cohort with BC from 2002 to 2017. Patient-level 1:1 matching was performed between pregnant and nonpregnant women. The study population was categorized into 6 biological subtypes based on the combination of prescribed therapies. Subanalyses were performed considering the time to pregnancy after BC diagnosis, systemic therapy, and pregnancy outcomes.
Results
We identified 544 matched women with BC, who were assigned to the pregnant (cases, n = 272) or nonpregnant group (controls, n = 272) of similar characteristics, adjusted for guaranteed bias. These patients were followed up for 10 years, or disease and mortality occurrence after the diagnosis of BC. Survival estimates were calculated. The actuarial 10-year overall survival (OS) rates were 97.4% and 91.9% for pregnant and nonpregnant patients, respectively. The pregnant group showed significantly better OS (adjusted hazard ratio [aHR], 0.29; 95% confidence interval [CI], 0.12–0.68; P = 0.005) and did not have a significantly inferior disease-free survival (aHR, 1.10; 95% CI, 0.61–1.99; P = 0.760).
Conclusion
Consistent outcomes were observed in every subgroup analysis. Our observational data provides reassuring evidence on the long-term safety of pregnancy in young patients with BC regardless of the BC biological subtype.

Keyword

Breast neoplasms; Korea; Long term effects; Pregnancy; Retrospective studies

Figure

  • Fig. 1 Flow diagram showing the process for selecting the study subjects and controls. BC, breast cancer; DCIS, ductal carcinoma in situ. Created using Microsoft PowerPoint 2016 (Microsoft, Redmond, WA, USA).

  • Fig. 2 Time-to-event curves for the overall survival for selective treatment groups. (A) HR, yes; HER2, no; chemotherapy, yes. (B) HR, no; HER2, yes; chemotherapy, yes. (C) HR, no; HER2, no; chemotherapy, yes. HR, hormone receptor (anti-hormonal therapy); HER2, human epidermal growth factor receptor 2 (target therapy). Created using SAS software (ver. 9.4; SAS Institute Inc., Cray, NC, USA).

  • Fig. 3 Time-to-event curves for disease-free survival for selective treatment groups. (A) HR, yes; HER2, no; chemotherapy, yes. (B) HR, yes; HER2, no; chemotherapy, no. (C) HR, no; HER2, no; chemotherapy, yes. HR, hormone receptor (anti-hormonal therapy); HER2, human epidermal growth factor receptor 2 (target therapy). Created using SAS software (ver. 9.4; SAS Institute Inc., Cray, NC, USA).


Reference

1. Kim BK, Ryu JM, Oh SJ, Han J, Choi JE, Jeong J, et al. Comparison of clinicopathological characteristics and prognosis in breast cancer patients with different Breast Imaging Reporting and Data System categories. Ann Surg Treat Res. 2021; 101:131–139. PMID: 34549036.
Article
2. Organisation for Economic Co-operation and Development (OECD). OECD family database [Internet]. Paris: OECD;2020. cited 2021 Apr 30. Available from: http://www.oecd.org/els/family/database.htm .
3. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society. J Clin Oncol. 2007; 25:2360–2368. PMID: 17515570.
Article
4. Lee SK, Kim SW, Yu JH, Lee JE, Kim JY, Woo J, et al. Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer? Breast Cancer Res Treat. 2019; 173:189–199. PMID: 30238275.
Article
5. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Danish Breast Cancer Cooperative Group. Pregnancy after treatment of breast cancer: a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 2008; 47:545–549. PMID: 18465320.
Article
6. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001; 19:1671–1675. PMID: 11250996.
Article
7. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 1994; 331:5–9. PMID: 8202106.
Article
8. Mueller BA, Simon MS, Deapen D, Kamineni A, Malone KE, Daling JR. Childbearing and survival after breast carcinoma in young women. Cancer. 2003; 98:1131–1140. PMID: 12973836.
Article
9. Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011; 47:74–83. PMID: 20943370.
Article
10. Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013; 31:73–79. PMID: 23169515.
Article
11. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ. 2007; 334:194. PMID: 17158581.
Article
12. Kranick JA, Schaefer C, Rowell S, Desai M, Petrek JA, Hiatt RA, et al. Is pregnancy after breast cancer safe? Breast J. 2010; 16:404–411. PMID: 20522097.
Article
13. Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018; 110:426–429. PMID: 29087485.
Article
14. Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005; 7:131–142. PMID: 15987443.
Article
15. Peccatori F, Cinieri S, Orlando L, Bellettini G. Subsequent pregnancy after breast cancer. Recent Results Cancer Res. 2008; 178:57–67. PMID: 18080443.
Article
16. Ives AD, Saunders CM, Semmens JB. The Western Australian gestational breast cancer project: a population-based study of the incidence, management and outcomes. Breast. 2005; 14:276–282. PMID: 16085234.
Article
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373–383. PMID: 3558716.
Article
18. Chow S, Wang H, Shao J. Sample size calculations in clinical research. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC;2008.
19. Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015; 24:201–207. PMID: 25662412.
Article
20. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, et al. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat. 2009; 117:319–324. PMID: 19137426.
Article
21. Azim HA Jr, Peccatori FA, de Azambuja E, Piccart MJ. Motherhood after breast cancer: searching for la dolce vita. Expert Rev Anticancer Ther. 2011; 11:287–298. PMID: 21342046.
Article
22. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002; 13:273–279.
Article
23. Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019; 125:307–316. PMID: 30335191.
Article
24. Li Y, Zhang Y, Wang S, Lu S, Song Y, Liu H. The effect of subsequent pregnancy on prognosis in young breast cancer patients (≤35 years old) according to hormone receptor status. Cancer Manag Res. 2021; 13:1505–1515. PMID: 33623430.
Article
25. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999; 17:855–861. PMID: 10071276.
Article
26. Sankila R, Heinävaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect”. Am J Obstet Gynecol. 1994; 170:818–823. PMID: 8141209.
Article
27. Nye L, Rademaker A, Gradishar WJ. Breast cancer outcomes after diagnosis of hormone-positive breast cancer and subsequent pregnancy in the tamoxifen era. Clin Breast Cancer. 2017; 17:e185–e189. PMID: 28185739.
Article
Full Text Links
  • ASTR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr